| Literature DB >> 33942712 |
Pedro Serrano-Aguilar1,2,3,4, Iñaki Gutierrez-Ibarluzea2,5,6, Pilar Díaz2,7, Iñaki Imaz-Iglesia2,3,8, Jesús González-Enríquez2,3,8, José Luis Castro2,9, Mireia Espallargues2,3,10, Sandra García-Armesto2,11, Paloma Arriola-Bolado2,12, Amado Rivero-Santana2,3,4,13, Lilisbeth Perestelo-Pérez1,2,3,4, Himar González-Pacheco2,13, Yolanda Álvarez-Pérez2,13, María José Faraldo-Vallés2,14, Janet Puñal-Riobóo2,14, Yolanda Ramallo-Fariña2,3,4,13, Luis María Sánchez-Gómez2,3,8,15, José Asua-Batarrita2,16, Eva Reviriego-Rodrigo2,16,17, Anai Moreno-Rodríguez18, Celia Juárez-Rojo2, Marisa Vicente-Saiz7, Eugenia Orejas-Pérez7, Jutta Knabe-Guerra2, Isabel Prieto-Yerro2,19, Cristina González Del Yerro-Valdés2,19.
Abstract
The Monitoring Studies (MS) program, the approach developed by RedETS to generate postlaunch real-world evidence (RWE), is intended to complement and enhance the conventional health technology assessment process to support health policy decision making in Spain, besides informing other interested stakeholders, including clinicians and patients. The MS program is focused on specific uncertainties about the real effect, safety, costs, and routine use of new and insufficiently assessed relevant medical devices carefully selected to ensure the value of the additional research needed, by means of structured, controlled, participative, and transparent procedures. However, despite a clear political commitment and economic support from national and regional health authorities, several difficulties were identified along the development and implementation of the first wave of MS, delaying its execution and final reporting. Resolution of these difficulties at the regional and national levels and a greater collaborative impulse in the European Union, given the availability of an appropriate methodological framework already provided by EUnetHTA, might provide a faster and more efficient comparative RWE of improved quality and reliability at the national and international levels.Entities:
Keywords: Decision making; Europe; Postlaunch evidence-generation studies; Real-world evidence; Technology assessment
Year: 2021 PMID: 33942712 DOI: 10.1017/S0266462321000295
Source DB: PubMed Journal: Int J Technol Assess Health Care ISSN: 0266-4623 Impact factor: 2.188